Ligand Pharmaceuticals Incorporated (LGND) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 3.66B |
| Enterprise Value | 3.93B |
| P/E Ratio | 122.06 |
| PEG Ratio | 14.59 |
| Price/Sales Ratio | 24.91 |
| Price/Book Ratio | 6.56 |
| Enterprise/Revenue | 29.24 |
| Enterprise/EBITDA | 92.16 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | September 30, 2026 |
| Profit Margin | 0.2 |
| Operating Margin | 0.12 |
| Return On Assets | 0.02 |
| Return On Equity | 0.05 |
| Revenue | 268.09M |
| Revenue/Share | 12.72 |
| Gross Profit | 261.5M |
| EBITDA | 192.74M |
| Net Income | 124.45M |
| Diluted EPS | 6.13 |
| Total Cash | 447.4M |
| Total Cash/Share | 22.41 |
| Total Debt | 1.15B |
| Total Debt/Equity | 1.2 |
| Current Ratio | 1.22 |
| Book Value Per Share | 48.18 |
| 52-Week Change | 66.87 |
| 52-Week High | 326.63 |
| 52-Week Low | 175.89 |
| Moving Average 50 Days | 297.47 |
| Moving Average 200 Days | 253.81 |
| Average Volume | 239,500 |
| Shares Outstanding | 20M |
| % Held by Institutions | 113.77 |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 1603:1000 |
| Last Split Date | November 02, 2022 |